NCT06585462CompletedPhase 1
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 82 (actual)
- First submitted
- 3 Sept 2024
- Start date
- 9 Sept 2024
- Primary completion date
- 16 Sept 2026
- Lead sponsor
- Amgen
- Diseases
- Obesity
- NCT number
- NCT06585462
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 82
- From 9 Sept 2024 to the primary completion date, 16 Sept 2026
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- History and/or clinical evidence of diabetes mellitus, including hemoglobin A1c ≥ 6.5% and/or a fasting glucose of ≥ 126 mg/dL (7 mmol/L) at screening.
- Triglycerides ≥ 5.65 mmol/L (i.e., 500 mg/dL) at screening.
Who the study is looking for
- Participants in the study will be males and females 18 to 65 years of age at the time of signing the informed consent with a body mass index (BMI) of 30.0 kg/m\^2 to 40.0 kg/m\^2 for Part A and BMI of 27.0 kg/m\^2 to 40.0 kg/m\^2 for Part B.
- Females enrolled must be of non-childbearing potential.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (13)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Anaheim Clinical Trials Coordinator of this site? Confirm its status | Anaheim | United States | Unknown status |
| Pinnacle Clinical Research Coordinator of this site? Confirm its status | Austin | United States | Unknown status |
| Translational Clinical Research LLC Coordinator of this site? Confirm its status | Aventura | United States | Unknown status |
| Lillestol Research, LLC Coordinator of this site? Confirm its status | Fargo | United States | Unknown status |
| Prime Health and Wellness Sky Clinical Research Network Group Coordinator of this site? Confirm its status | Fayette | United States | Unknown status |
| Clinical Neuroscience Solutions - Jacksonville Coordinator of this site? Confirm its status | Jacksonville | United States | Unknown status |
| Orange County Research Center Coordinator of this site? Confirm its status | Lake Forest | United States | Unknown status |
| South Florida Clinical Research Institute - Lauderhill Coordinator of this site? Confirm its status | Lauderhill | United States | Unknown status |
| New Horizon Research Center Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| Clinical Pharmacology of Miami, LLC Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| Clinical Neuroscience Solutions Coordinator of this site? Confirm its status | Orlando | United States | Unknown status |
| Fomat Medical Research Coordinator of this site? Confirm its status | Oxnard | United States | Unknown status |
| Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group Coordinator of this site? Confirm its status | Union City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.